



Previously Westinghouse Homewood

820 WASHINGTON BOULEVARD  
PITTSBURGH, PA 15206  
(412) 665-2700  
1-800-777-1172  
FAX: (412) 665-2745

January 8, 2016

Document Control Desk  
U.S. Nuclear Regulatory Commission  
Washington, DC 20555-0001

Subject: Pursuant to 10 CFR Part 21, Defect on Irradiations testing performed by Steris Isomedix Services (Steris) in Whippany, New Jersey.

Reference: NTS Letter dated December 14, 2015 received by Homewood Products Corporation December 22, 2015.

### Background

Homewood Energy Services was notified by NTS (Formerly Wyle Laboratories) on December 22, 2015 of a defect in irradiation services performed by Steris Isomedix. The defect is an error in reporting the variability in the dose delivered or lack thereof on the Isomedix Certificate of Processing for the Whippany, NJ facility. The U.S. Nuclear Regulatory Commission (NRC) under 10 CFR Part 50, Appendix B issued a Notice of Nonconformance 99901145/2014-201-01 to Steris stating that the measuring and testing equipment used to determine the applied radiation dose reported on the Isomedix Certificate of Processing provided with each gamma irradiation run did not account for all the uncertainties involved (i.e. density of unrelated products in carriers, off-carrier locations within the irradiator, and Cobalt-60 source decay) and therefore the actual radiation dose applied to components could be less than requested as reported on the Certificate of Processing.

Steris Isomedix Services completed an evaluation of the dose rate variability of items processed in off-carrier locations in the irradiator. Steris Isomedix Services Position Paper dated 4/27/15 states the overall variability (uncertainty) associated with gamma radiation exposures at their Whippany NJ facility.

IERD  
NMSS

### Evaluation

Homewood Products has put together the necessary resources to evaluate the reported defect, and has determined that the defect could create a substantial safety hazard.


Our plan to determine if the defect is in fact a substantial safety hazard is as follows:

1. The potential defect will be reported to all Homewood Products customers (licensees) where the reported dose was revised based on the NTS letters and Steris revised certificates. In most cases, we used additional margins beyond the requirements of IEEE 323.
2. We will work with customers to determine if this defect has an impact that results in a substantial safety hazard.

As documented in our notification to the NRC on December 23, 2015 we will complete the final evaluation within sixty (60) days of our initial evaluation dated January 8, 2016. Based on the customer (licensees) evaluation, a final evaluation will be made whether a substantial safety hazard exists or not.

If you should have any questions, please contact;

Sincerely,

A handwritten signature in black ink, appearing to read "Barry DeGroot". The signature is fluid and cursive, with the first name "Barry" being the most prominent part.

Barry DeGroot, President  
Homewood Products Corp  
Telephone: 412 665-2700